LIPELLA PHARMACEUTICALS INC. (LIPO): Nasdaq/NYSE listing notice — Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets

LIPELLA PHARMACEUTICALS INC.

Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.
Non-compliance with Listing Rules 5635(d) and 5640 due to Series C preferred and warrants issued in Dec 2024-Mar 2025 private placements.
Common stock now quoted on OTC Markets under symbol LIPO; company exploring other listing venues.
Company disappointed, states business fundamentals intact; continuing clinical development of LP-10 and LP-310.
Lipella remains an SEC reporting company and will continue filing periodic reports.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

LIPELLA PHARMACEUTICALS INC. received a nasdaq delisting notice notice regarding other (rules 5100, 5635(d), 5640).

Exchange: nasdaq
Notice: delisting notice
Rules: 5100, 5635(d), 5640

Exact text from the filing

June 17, 2025, indicating that the Panel has determined to delist the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5100, which permits Nasdaq to use its discretionary authority for public interest concerns, due to the Company’s non-compliance with (i) Nasdaq Listing Rule 5635(d), which requires prior shareholder approval for the issuance, other than in a public offering, of 20% or more of a company’s outstanding shares at a per share price less than the Minimum Price (as defined in such rule), and (ii)

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-25-000984

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.